Latigo Biotherapeutics, Inc. (LTGO)

21.08 -1.47 (-6.52%) USD  |  NASDAQ  |  Sep 21, 16:00
20.70 -0.38 (-1.80%) After-Hours: 20:00
More

Latigo Biotherapeutics Net Income (Quarterly) : -25.80M for June 30, 2026

Net Income (Quarterly) Chart

View Net Income (Quarterly) for LTGO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Net Income (Quarterly) Chart
Start Trial

Historical Net Income (Quarterly) Data

View and export this data back to 2025. Start Trial.
Date Value
June 30, 2026 -25.80M
March 31, 2026 -22.96M
Date Value
June 30, 2025 -25.84M
March 31, 2025 -20.95M

Net Income Definition

Represents net income for the period and date(s) requested in local currency by default.

Read full definition.

Net Income (Quarterly) Range, Past 5 Years

View Net Income (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Net Income (Quarterly) Benchmarks

View Net Income (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 23.00M
Corcept Therapeutics, Inc. 42.14M
Veru, Inc. -6.988M
Johnson & Johnson 5.534B
Eli Lilly & Co. 7.095B

Net Income (Quarterly) Related Metrics

Total Expenses (Quarterly) 25.80M
EPS Diluted (Quarterly) -0.3891
Enterprise Value 1.760B
Earnings Yield -7.08%
Normalized Earnings Yield -7.032